Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 21, 2026
TickeronGET DAILY SIGNALS
Globe Life (GL) Q3 2026 Earnings: Core Stability Tested by Health Segment Pressure

Globe Life (GL) Q3 2026 Earnings: Core Stability Tested by Health Segment Pressure

Key Takeaways

  • Globe Life reported net income of $361.1 million, or $4.62 per diluted share, down from $4.73 per share in the prior-year quarter.
  • Net operating income was $4.84 per diluted share, narrowly above the $4.81 recorded a year earlier but below consensus expectations.
  • Total revenue rose 5.2% year over year to $1.60 billion, slightly under analyst estimates of $1.61 billion.
  • A swing to an underwriting loss at the United American health unit, driven by high-severity claims and a Medicare claims processing delay, pressured results.
  • Full-year 2026 net operating income guidance was trimmed, while the company introduced 2027 guidance and raised its share buyback target.

Why This Quarter Matters

Globe Life Inc. (GL) is a Texas-based insurance holding company offering life insurance, supplemental health insurance, and annuities through several distribution channels. Its third-quarter 2026 results matter because the company has built a reputation for steady, predictable underwriting and strong capital returns. Investors watch this report closely for signs of deterioration in claims trends, which can signal pricing or underwriting stress across the insurance industry. The quarter tested that narrative, as a sharp reversal in one health segment overshadowed otherwise stable results and prompted management to recalibrate its full-year outlook, making the report a key read on the durability of Globe Life's core earnings power. To put the numbers in broader context, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The Numbers in Detail

For the third quarter ended September 30, 2026, Globe Life reported net income of $361.1 million, or $4.62 per diluted share, down from $387.8 million, or $4.73 per share, in the year-ago quarter. Net operating income, a non-GAAP metric the company uses to reflect underlying performance, was $378.8 million, or $4.84 per diluted share, compared with $394.2 million, or $4.81 per share, a year earlier.

Total revenue increased 5.2% year over year to $1.60 billion, slightly below the consensus estimate of $1.61 billion. Net premiums earned rose 6.5% to $1.31 billion, roughly in line with expectations. GAAP earnings per share of $4.62 and operating earnings of $4.84 per share both came in below consensus forecasts, which stood near $4.85 to $4.89 per share.

The primary drag was the United American health segment, which swung from a $16.1 million underwriting gain a year ago to a $6.4 million underwriting loss. Management attributed the reversal to high-severity claims at Evry, a developing group health business, and a claims processing delay at the Centers for Medicare and Medicaid Services (CMS) that pushed roughly $7 million of excess Medicare Supplement claims into the quarter. Partially offsetting this, net investment income rose 3%, and the fixed maturity portfolio earned a taxable equivalent effective yield of 5.33%, up from 5.26% a year earlier.

Market Reaction

Globe Life shares traded down roughly 6.5% to about $158.50 immediately after the results, reflecting investor disappointment that both earnings per share and revenue landed below consensus estimates. The market's focus centered on the underwriting loss at United American and the guidance reduction that followed, even though management characterized the pressures as isolated rather than systemic. The raised buyback target and the introduction of 2027 guidance signaled management's confidence, but the negative reaction suggests investors weighed the near-term earnings shortfall and the segment-level claims volatility more heavily than the longer-term capital return story.

Forward Outlook and What to Watch

Globe Life adjusted its full-year 2026 net operating income guidance to a range of $15.35 to $15.65 per share, citing the two items affecting the United American General Agency division. Importantly, management framed these as discrete events rather than a change in the underlying core business, and introduced 2027 net operating income guidance of $16.10 to $17.10 per share, representing roughly 7.1% growth at the midpoint.

Investors will want to watch whether the high-severity claims at Evry persist or normalize as that group health business scales, and whether the Medicare Supplement claims timing issue fully resolves in the fourth quarter. Underwriting margin trends, excluding assumption updates, will also be a key indicator of pricing discipline.

On the capital front, the company repurchased 1.1 million shares for $185 million during the quarter and raised its full-year 2026 buyback outlook to between $725 million and $775 million. Sustained investment income growth, the yield on the fixed maturity portfolio, and the pace of share repurchases will all remain important factors for shareholders monitoring the company's path toward its 2027 targets.

One Tool That Helps with Earnings Analysis

One tool I’ve found useful for digging into post-earnings moves and comparing peers is Tickeron’s AI Screener. It lets me filter equities by industry, performance metrics, and technical signals to quickly surface relevant ideas and put recent developments into broader context. I typically spend just a few minutes running a screen after reports like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for GL turns negative, indicating new downward trend

GL saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned negative. In 47 of the 104 cases, the stock moved further down in the following days. The odds of a decline are at 45%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 18 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 39%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.

The Aroon Indicator for GL entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for GL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where GL advanced for three days, in 216 of 377 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

GL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. GL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.962) is normal, around the industry mean (1.337). P/E Ratio (10.273) is within average values for comparable stocks, (19.773). GL's Projected Growth (PEG Ratio) (1.360) is slightly higher than the industry average of (0.463). Dividend Yield (0.008) settles around the average of (0.047) among similar stocks. P/S Ratio (2.251) is also within normal values, averaging (1.303).

The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are MetLife (NYSE:MET), Prudential Financial (NYSE:PRU), Lincoln National Corp (NYSE:LNC), Genworth Financial (NYSE:GNW).

Industry description

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Life/Health Insurance Industry is 18.5B. The market cap for tickers in the group ranges from 228.36K to 140.68B. CILJF holds the highest valuation in this group at 140.68B. The lowest valued company is GWGHQ at 228.36K.

High and low price notable news

The average weekly price growth across all stocks in the Life/Health Insurance Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -9%. SNFCA experienced the highest price growth at 0%, while ABX experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Life/Health Insurance Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 91
Profit Risk Rating: 61
Seasonality Score: 9 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, which engages in the provision of individual life and supplemental health insurance products and services

Industry LifeHealthInsurance

Industry
N/A
Address
7677 Henneman Way
Phone
+1 972 569-4000
Employees
3695
Web
https://www.globelifeinsurance.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.